Drug intelligence / Profile preview

aminophenazone + caffeine + chlorphenamine

Development stage
Unknown
Lead developer
Anke Bio
Modality
Small Molecules
Administration
Oral
01

Overview

aminophenazone + caffeine + chlorphenamine is a fixed-dose combination medication developed and marketed by Anke Bio for the symptomatic relief of the common cold and influenza. The formulation consists of three active ingredients: aminophenazone, an analgesic and antipyretic that reduces fever and pain by inhibiting cyclooxygenase (COX) enzymes; chlorphenamine maleate, a first-generation antihistamine that acts as a histamine H1 receptor antagonist to relieve symptoms such as sneezing, rhinorrhea, and watery eyes; and caffeine, a central nervous system stimulant that acts as an adenosine receptor antagonist. Caffeine is included to enhance the analgesic efficacy of aminophenazone and to mitigate the sedative effects commonly associated with chlorphenamine. This combination is approved in China and is typically administered orally in capsule form for the treatment of fever, headache, sore throat, and nasal congestion.

Brand names
氨咖黄敏胶囊速效伤风胶囊
Other names
Aminophenazone-Caffeine-ChlorphenamineRapid Cold Relief CapsulesAn Ka Huang Min Jiao NangSu Xiao Shang Feng Jiao Nang
02

Targets

ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on aminophenazone + caffeine + chlorphenamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on aminophenazone + caffeine + chlorphenamine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call